Abstract Body

Background: The United States (US) Centers for Disease Control recently introduced the Limited Antigen-Avidity enzyme immunoassay (LAg-Avidity assay), a new, commercially-available, cross-sectional HIV incidence assay. We analyzed factors associated with misclassification by the LAg-Avidity assay among men who have sex with men and persons who inject drugs living in the US with long-term (2+ years) infection. Methodology: Samples were obtained from the Multicenter AIDS Cohort Study (MACS), and AIDS Linked to the IntraVenous Experience (ALIVE) cohorts (1089 samples from 666 individuals: 612 samples collected 2-4 years after seroconversion and 477 samples collected 5-8 years after seroconversion). Paired samples from both time points were available for 423 (63.5%) of the 666 individuals. Samples were tested with the LAg-Avidity assay using an assay cutoff of ≤1.5 normalized optical density units (OD-n). Samples with results ≤1.5 OD-n were considered to be misclassified. Results: Overall, 4.8% (52/1089) of the samples were misclassified by the LAg-Avidity assay. The percentages of samples that were misclassified for different sample subsets were as follows. Overall: 4.8% (52/1089); individuals who reported that they were not on antiretroviral treatment (ART): 3.3% (26/790); individuals with viral loads >400 copies/mL: 1.8% (16/884); individuals with viral loads >400 copies/mL who also had CD4 counts >200 cells/ul: 1.4% (10/705), 95% CI: 0.68-2.60). Age, race, gender and mode of HIV acquisition were not associated with misclassification. In an adjusted analysis, viral load <400 copies/mL (adjusted odds ratio [aOR]: 3.72, 95% CI: 1.61-8.57), CD4 <50 cells/ul (aOR: 5.41, 95% CI: 1.86-15.74) and have a low LAg-Avidity result (≤1.5 OD-n) from an earlier time point (aOR: 5.60, 95% CI: 1.55-20.25) were significantly associated with misclassification. Self-reported ART was not associated with misclassification in the adjusted analysis. Conclusions: Individuals who are misclassified by the LAg-Avidity assay are likely to be misclassified for the duration of their infection. The current recommendations for the LAg-Avidity assay indicate that individuals on HAART and elite suppressors and AIDS (CD4 <200 cells/ul) should be excluded from analysis does not completely remove all sources of misclassification among long-term infected individuals.